Prostate Basal Cell Carcinoma: A Case Report

Prostate basal cell carcinoma (PBCC) accounts for 0.01% of all prostate cancers. A 68-year-old man complained of dysuria for 5 years on his initial visit. His PSA level was 3.87 ng/mL. Due to a diagnosis of benign prostate hyperplasia, he underwent transurethral resection of the prostate. A pathological examination revealed that basal cell-like atypical cells made alveolar with palisadal layout. Immunohistochemical analysis showed positive 34β12, P63, and Ki-67. Based on these findings, PBCC was diagnosed. Then, we performed radical prostatectomy. He was free from recurrence 22 months after the operation. We herein report an extremely rare case of PBCC.

Download Full-text

Basal Cell Carcinoma of Prostate With MSMB–NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report

International Journal of Surgical Pathology ◽

10.1177/10668969211017321 ◽

2021 ◽

pp. 106689692110173

Author(s):

Vilde Pedersen ◽

Katrine S. Petersen ◽

Klaus Brasso ◽

Olga Østrup ◽

Anand C. Loya

Keyword(s):

Prostate Cancer ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Carcinoma In Situ ◽

Pathological Examination ◽

Molecular Characteristics ◽

Histological Lesion ◽

Basal Cell Carcinomas

Basal cell carcinomas of prostate (BCCP) are very rare. Most arise in the transition zone and thus are associated with lower urinary tract symptoms and rarely associated with elevated prostate-specific antigen (PSA). These features make diagnosis/early diagnosis difficult because of the routine protocols followed. Basal cell carcinomas have distinctive histopathological, immunohistochemical, and to some extent also different molecular characteristics. Basal cell carcinoma in situ (BCCIS) is a nonexistent histological lesion as per the current literature, but here is an attempt to describe it through this case. A 74-year-old man presented with hematuria and previous diagnosis of prostatic hyperplasia. Based on this history, he underwent a prostatectomy ad modum Freyer. Pathological examination surprisingly revealed a diffusely infiltrative tumor with nonacinar adenocarcinoma morphology and many glandular structures probably representing BCCIS. Tumor was diagnosed as BCCP. Patient presented with metastasis to the abdominal wall 8 months postprostatectomy. BCCP is an aggressive type of prostate cancer, which might be challenging to diagnose based on routine protocols. This results in delayed diagnosis and treatment and thus poor prognosis. Furthermore, patients with this subtype of prostate cancer need appropriately designed, and maybe a totally different follow-up regimen as PSA is of no use for BCCP patients. Finally, diagnosis of BCCIS, if agreed upon its existence needs to be studied in larger cohorts as a precursor lesion.

Download Full-text

Metastatic Basal Cell Carcinoma: Four Case Reports, Review of Literature, and Immunohistochemical Evaluation

Archives of Pathology & Laboratory Medicine ◽

10.5858/2006-130-45-mbccfc ◽

2006 ◽

Vol 130 (1) ◽

pp. 45-51

Author(s):

Diana N. Ionescu ◽

Muammar Arida ◽

Drazen M. Jukic

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Case Reports ◽

Small Sample ◽

Ki 67 ◽

Immunohistochemical Markers ◽

Metastatic Basal Cell Carcinoma ◽

Metastatic Sites

Abstract Context.—Metastatic basal cell carcinoma (BCC) is relatively rare and is seldom considered a complication in the routine treatment and follow-up of patients with BCC. Although multiple studies have tried to distinguish aggressive from nonaggressive BCCs, to our knowledge, no consistent clinical, histopathologic, or immunohistochemical features have yet been reported. Objective.—To report 4 cases of metastatic BCCs and to evaluate these in addition to known nonmetastatic BCCs with specific immunostains in an attempt to find distinct morphologic or immunohistochemical patterns that could be helpful in identifying aggressive BCCs. Design.—We reviewed 4 cases of metastatic BCCs and recorded the clinical and morphologic findings. We then searched our archives for 14 cases of BCC that followed the usual nonaggressive course. We evaluated these 18 cases with immunohistochemical stains for Ki-67, p53, and bcl-2. Results.—In metastasizing BCC, Ki-67 staining was slightly higher in metastatic sites than in primary sites (average 63% and 51%, respectively). p53 was expressed in 3 of 4 primary sites and 2 of 4 metastatic sites. Bcl-2 was positive in both primary and metastatic sites in 3 of 4 cases. In the 14 cases of nonaggressive BCC, staining for Ki-67 averaged 38%, p53 was positive in 11 cases, and Bcl-2 staining was noted in 13 cases. Conclusions.—Overall, in the small sample that we evaluated, the immunohistochemical markers for Ki-67, p53, and Bcl-2 did not distinguish between metastatic and nonaggressive BCCs.

Download Full-text

Immunohistochemical evaluation of trichoepithelioma and basal cell carcinoma using Ki-67

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.02.348 ◽

2015 ◽

Vol 72 (5) ◽

pp. AB84

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Ki 67

Download Full-text

Basal cell carcinoma in a patient with Wiskott-Aldrich syndrome: an immunohistochemical analysis of infiltrating cells around the tumour

European Journal of Dermatology ◽

10.1684/ejd.2020.3815 ◽

2020 ◽

Vol 30 (4) ◽

pp. 421-422

Author(s):

Hind Al-Busani ◽

Takeshi Namiki ◽

Yusuke Yoshioka ◽

Tsukasa Ugajin ◽

Keiko Miura ◽

...

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Immunohistochemical Analysis ◽

Wiskott Aldrich Syndrome ◽

Infiltrating Cells

Download Full-text

Regression in basal cell carcinoma: an immunohistochemical analysis

British Journal of Dermatology ◽

10.1111/j.1365-2133.1994.tb06873.x ◽

1994 ◽

Vol 130 (1) ◽

pp. 1-8 ◽

Cited By ~ 85

Author(s):

M.J. HUNT ◽

G.M. HALLIDAY ◽

D. WEEDON ◽

B.E. COOKE ◽

R. StC. BARNETSON

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Immunohistochemical Analysis

Download Full-text

Biochemical and immunohistochemical analysis of keratins in basal cell carcinoma

Journal of Dermatological Science ◽

10.1016/s0923-1811(98)83323-9 ◽

1998 ◽

Vol 16 ◽

pp. S55

Author(s):

Ken-ichi Yoshikawa ◽

Yohtaro Katagata ◽

Shigeo Kondo

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Immunohistochemical Analysis

Download Full-text

Ki-67 and p53 expression in basal cell carcinoma

Journal of Dermatological Science ◽

10.1016/s0923-1811(98)83698-0 ◽

1998 ◽

Vol 16 ◽

pp. S117

Author(s):

Zita Battyáni ◽

Erzsébet Zombai ◽

György Szekeres

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Ki 67 ◽

P53 Expression

Download Full-text

Immunohistochemical evaluation of proliferative activity (Ki-67 index) in different histological types of cutaneous basal cell carcinoma

Biologia ◽

10.2478/s11756-012-0035-8 ◽

2012 ◽

Vol 67 (3) ◽

Cited By ~ 1

Author(s):

Vladimír Bartoš ◽

Katarína Adamicová ◽

Milada Kullová ◽

Martin Péč

Keyword(s):

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Basal Cell ◽

Proliferative Activity ◽

Prognostic Significance ◽

Biological Behavior ◽

Ki 67 ◽

Primary Tumors ◽

Histological Types ◽

Proliferation Activity

AbstractEvaluation of tumor cell proliferation status belongs to the basic prognostic indicators in a routine biopsy report. In cutaneous basal cell carcinoma (BCC), however, there are discrepancies about a true prognostic significance of this histopathological parameter. The aim of this study was to assess a proliferative activity (Ki-67 index) in BCCs of the skin. Biopsy specimens from 80 cutaneous BCCs (63 primary, 17 recurrent) of different histological types from 75 subjects (34 men, 41 women) were enrolled into this study. All samples were immunohistochemically stained by antibody against Ki-67 antigen (DAKO, clone MIB-1, dilution 1:100). For the statistical analysis, χ 2 test was employed. We found a striking percentage variability of nuclear Ki-67 expression in individual tumors (range 2–70%). Mean value of Ki-67 index was 27.4% (in primary tumors 28.1 %, in recurrent lesions 25.6%). The highest Ki-67 expression occurred in infiltrative BCCs (average 38.1%), morpheaform BCCs (average 37.0%), and superficial BCCs (average 35.7%), the lowest expression was recorded in nodular BCCs (average 21.7%) and BCCs with adnexal (trichoepithelial) differentiation (18.6%). There were not persuasive and statistically significant quantitative differences in proliferation activity of tumor cells between the individual histological BCC types, as well as between primary and recurrent lesions. A distribution of Ki-67 positive cells in tumor nests was mostly irregular and areas with a high number of Ki-67 labeled cells often occurred adjacent to areas with a lower number of cells expressing this marker. Because of a marked Ki-67 staining variability, we can conclude that the simple quantification of BCC proliferation activity alone may not be sufficient for the prediction of further biological behavior, evolution and clinical outcome of this malignancy.

Download Full-text